Multiple studies over the years have linked PVL to an increased risk of adverse outcomes. New research out of Italy, however, suggests that device improvements made by Medtronic, Edwards Lifesciences and Boston Scientific may have reduced PVL's influence.

Surgery offers multiple long-term benefits when compared to a more interventional approach, though it is still associated with certain risks of its own. In the end, researchers agree, the decision is one that should involve input from surgeons, cardiologists and others.

Gilbert Tang, MD, explains how transcatheter tricuspid TEER and total valve replacement options will likely lead to higher tricuspid valve surgical volumes in the years ahead.

Bioprosthetic valves are being used more and more for aortic valve replacement, but mechanical valves appear to provide better long-term outcomes for patients 60 and younger. The new study, based on data from nearly 110,000 patients, was presented at STS 2025 and published in the Journal of the American College of Cardiology.

Cardiologists believe this is the first time this exact complication has been reported. Even patients who present with no known risk factors, they said, should receive regular follow-up care to ensure such incidents do not go untreated. 

The presentations will cover a variety of topics, including coronary artery disease, semaglutide, artificial intelligence, TAVR, heart failure, PCI and much more. ACC.25 takes place March 29-31 in Chicago.

Researchers have made it a priority to learn as much about the durability of TAVR valves as possible. A new study in JACC: Cardiovascular Interventions used updated VARC-3 definitions to identify signs of hemodynamic valve deterioration in nearly 2,500 patients.

Meril Life Sciences has been manufacturing its Myval heart valves for years. The devices are approved and available in both India and Europe, but they have not been approved by the FDA.